The acquisition brings a first-in-class anti-CD122 antibody, FB102, into the immunology pipeline, targeting large unmet needs in vitiligo and celiac disease, with potential for broader autoimmune indications. The $2.2B cash deal leverages proven development and commercialization strategies to maxim…
The acquisition of Forte for $2.2B in cash brings a first-in-class anti-CD122 antibody, FB102, into the immunology portfolio, targeting high unmet needs in vitiligo and celiac disease. The deal, expected to close in Q3 2026, aligns with long-term growth and Vision 2030.Original document: argenx SE…
Shares of Forte Biosciences (FBRX) surged nearly 40% in premarket trading Monday after Argenx (ARGX) agreed to acquire the clinical-stage biotech company in an all-cash deal valued at approximately $2.2 billion, giving the immunology specialist a promising autoimmune therapy that it believes could…
argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, and Forte Biosciences, Inc. (Nasdaq: FBRX) today announced that the companies have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77 per share in cash, representing a total equity…
Q2 2026 saw record revenue growth of 60% year-over-year, driven by VYVGART's strong performance in MG and CIDP, including the seronegative MG launch. Pipeline progress and label expansions are set to sustain long-term growth, with robust financials and disciplined capital allocation.Based on argenx…
Q2 2026 saw record revenue growth of 60% year-over-year, driven by VYVGART's expansion in MG and CIDP, including the new seronegative MG approval. Strong pipeline progress and disciplined capital allocation support long-term growth, with multiple late-stage readouts expected this year.Based on arge…
Q2 2026 saw 60% year-over-year sales growth, driven by expanded VYVGART indications and robust pipeline progress. Profitability and liquidity improved significantly, with key registrational study readouts expected in the second half of 2026.Original document: argenx SE [ARGX] Earnings Release — Jul…
(14:51 GMT) argenx Price Target Raised to $1088.00/Share From $1016.00 by B of A Securities
